Welcome to our dedicated page for KEWAUNEE SCIENTIFIC /DE/ SEC filings (Ticker: KEQU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KEWAUNEE SCIENTIFIC /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KEWAUNEE SCIENTIFIC /DE/'s regulatory disclosures and financial reporting.
Phillips Elizabeth D reported acquisition or exercise transactions in this Form 4 filing.
KEWAUNEE SCIENTIFIC CORP senior vice president of People & Culture, Elizabeth D. Phillips, received a compensation grant of 2,466 restricted stock units tied to the company’s common stock. Each unit represents a contingent right to one share and will vest in three equal annual installments beginning on June 30, 2027, subject to her continued employment. Following this award, her reported holdings from this grant total 2,466 units.
Ranade Mandar reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific senior vice president of IT & Engineering Mandar Ranade received a grant of 2,635 restricted stock units tied to the company’s common stock. Each unit represents a right to one share. The award will vest in three equal annual installments beginning on June 30, 2027, contingent on continued employment.
Noble Ryan S. reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific reported that senior vice president of Sales & Marketing Development Ryan S. Noble received a grant of 2,628 Restricted Stock Units (RSUs) for FY27 on June 24, 2026. Each RSU represents a contingent right to receive one share of common stock. The RSUs vest in three equal annual installments beginning June 30, 2027, subject to his continued employment with the company. Following this compensation-related award, Noble holds 2,628 RSUs linked to Kewaunee Scientific common stock.
Batdorff Douglas J. reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific senior vice president of manufacturing operations Douglas J. Batdorff received a grant of 2,717 restricted stock units tied to the company’s common stock. Each unit represents a right to one share. Following this grant, he holds 2,717 restricted stock units directly.
The award will vest in three equal annual installments beginning on June 30, 2027, and is contingent on his continued employment with the company. This is a compensation-related equity grant rather than an open-market stock purchase or sale.
Gardner Donald T. III reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific reported that Chief Financial Officer Donald T. Gardner III received a compensation-related grant of derivative securities. He was awarded 5,428 restricted stock units linked to the company’s common stock, with each unit representing the right to receive one share in the future.
The restricted stock units will vest in three equal annual installments beginning on June 30, 2027, conditioned on his continued employment with the company. Following this grant, his reported holding of these FY27 restricted stock units is 5,428 units.
HULL THOMAS DAVID III reported acquisition or exercise transactions in this Form 4 filing.
KEWAUNEE SCIENTIFIC CORP President & CEO Thomas David Hull III reported an equity compensation grant in the form of restricted stock units. He received 15,195 RSUs tied to the company’s common stock, each representing a contingent right to one share, with no cash paid per unit.
The RSUs will vest in three equal annual installments starting on June 30, 2027, as long as he remains employed by the company. Following this award, his reported holdings for this RSU grant total 15,195 units directly.
Kewaunee Scientific Corporation reported fiscal year 2026 sales of $281,999,000, up 17.3% from the prior year, reflecting growth in both its Lab Products Group and International segments. Full-year net earnings were $9,618,000, with diluted EPS of $3.22, compared to $3.83 a year earlier.
EBITDA for the year was $22,425,000, slightly above the prior year, while adjusted EBITDA reached $23,210,000 after excluding Nu Aire integration costs. The company reduced long-term debt to $40,851,000 and improved its debt-to-equity ratio to 0.61-to-1, ending the year with order backlog of $165.9 million. Fourth-quarter sales were $71,400,000, with net earnings of $3,388,000 and diluted EPS of $1.13.
Kewaunee Scientific Corporation filed a current report stating it will release financial results for its fourth quarter and fiscal year ended April 30, 2026 on June 23, 2026 after the close of trading. The results will be posted on the company’s website.
The filing also highlights Kewaunee’s global business in laboratory, healthcare, and technical furniture, and notes its newly acquired subsidiary Nu Aire, a manufacturer of biological safety cabinets and other laboratory equipment. The press release includes standard forward-looking statement language outlining various business risks and uncertainties.
Campbell John Jette reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific director John Jette Campbell received an equity grant of 2,013 shares of Common Stock as part of his annual compensation. The shares were awarded at no cash cost under the company’s 2023 Omnibus Incentive Plan, increasing his directly held position to 2,703 shares after the award.
GEHL KEITH M reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific director Keith M. Gehl received a grant of 2,013 shares of Common Stock on May 1, 2026. The shares were awarded under the company’s 2023 Omnibus Incentive Plan as the equity portion of his annual compensation and were granted at $0.00 per share. Following this award, he directly holds 22,409 shares of Kewaunee Scientific common stock.